Matthew Ros Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Matthew Ros.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Matthew Ros. Matthew Ros is Chief Operating Officer in Epizyme, Inc. ($EPZM) and See Remarks in Epizyme, Inc. ($EPZM) and Director in Unum Therapeutics Inc. ($UMRX).
Latest Insider Trading Transactions of Matthew Ros
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 05 2021 | COGT | Cogent Biosciences ... | Ros Matthew | Director | Option Exercise | A | 9.08 | 2,068 | 18,777 | 2,068 | |
Mar 15 2021 | UMRX | Cogent Biosciences ... | Ros Matthew | Director | Option Exercise | A | 8.45 | 60,000 | 507,000 | 60,000 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | A | 11.02 | 134,178 | 1,478,642 | 134,178 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 28,125 | 0 | 84,082 | 56 K to 84.1 K (+50.26 %) |
Jan 27 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 11.41 | 2,872 | 32,770 | 55,957 | 58.8 K to 56 K (-4.88 %) |
Jan 06 2021 | UMRX | Cogent Biosciences ... | Ros Matthew | Director | Option Exercise | A | 7.62 | 1,641 | 12,503 | 1,641 | |
Oct 02 2020 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 2.26 | 9,247 | 20,898 | 9,247 | |
Jul 06 2020 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 0.47 | 35,280 | 16,582 | 35,280 | |
Jun 30 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 16.15 | 2,728 | 44,057 | 57,507 | 60.2 K to 57.5 K (-4.53 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 6,000 | 0 | 60,235 | 54.2 K to 60.2 K (+11.06 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 9.58 | 68,651 | 657,677 | 104,787 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 12.45 | 2,289 | 28,498 | 107,577 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 9.12 | 41,063 | 374,495 | 110,557 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 21.65 | 68,651 | 1,486,294 | 51,798 | 120.4 K to 51.8 K (-57.00 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 9.58 | 68,651 | 657,677 | 120,449 | 51.8 K to 120.4 K (+132.54 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 22.00 | 2,289 | 50,358 | 51,798 | 54.1 K to 51.8 K (-4.23 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 12.45 | 2,289 | 28,498 | 54,087 | 51.8 K to 54.1 K (+4.42 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 20.50 | 41,063 | 841,792 | 51,798 | 92.9 K to 51.8 K (-44.22 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 9.12 | 41,063 | 374,495 | 92,861 | 51.8 K to 92.9 K (+79.28 %) |
Jun 11 2020 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 0.63 | 14,331 | 9,029 | 14,331 | |
Apr 08 2020 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 0.35 | 49,887 | 17,436 | 49,887 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | A | 21.39 | 56,213 | 1,202,396 | 56,213 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 11,688 | 0 | 51,478 | 39.8 K to 51.5 K (+29.37 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Payment of Exercise | F | 22.40 | 2,395 | 53,648 | 39,790 | 42.2 K to 39.8 K (-5.68 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 24.64 | 1,847 | 45,510 | 42,185 | 44 K to 42.2 K (-4.19 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 5,000 | 0 | 44,032 | 39 K to 44 K (+12.81 %) |
Oct 03 2019 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 1.41 | 12,509 | 17,638 | 12,509 | |
Jul 29 2019 | UMRX | Unum Therapeutics ... | Ros Matthew | Director | Option Exercise | A | 2.05 | 28,661 | 58,755 | 28,661 | |
Jun 14 2019 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 12.10 | 1,185 | 14,339 | 39,032 | 40.2 K to 39 K (-2.95 %) |
Jun 14 2019 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 4,000 | 0 | 40,217 | 36.2 K to 40.2 K (+11.04 %) |
Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 0.00 | 32,894 | 0 | 36,217 | 3.3 K to 36.2 K (+989.89 %) |
Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 0.00 | 32,894 | 0 | 36,217 | 3.3 K to 36.2 K (+989.89 %) |
Feb 13 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 16.00 | 106,344 | 1,701,504 | 106,344 | |
Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | M | 9.58 | 72,264 | 692,289 | 0 | |
Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Sell | S | 17.20 | 519 | 8,927 | 2,603 | 3.1 K to 2.6 K (-16.62 %) |
Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Sell | S | 16.63 | 71,745 | 1,192,768 | 3,122 | 74.9 K to 3.1 K (-95.83 %) |
Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Buy | M | 9.58 | 72,264 | 692,289 | 74,867 | 2.6 K to 74.9 K (+2,776.18 %) |
Mar 02 2017 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 6.21 | 1,708 | 10,613 | 1,708 | 0 to 1.7 K |
Feb 09 2017 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 12.45 | 109,866 | 1,367,832 | 109,866 | |
May 17 2016 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 9.58 | 173,438 | 1,661,536 | 173,438 |
Page: 1